Your browser is out-of-date!

Update your browser to view this website correctly.

1Cookies

2Disclaimer

A resilient Q1 2026 performance saw outperformance versus the Nasdaq Biotechnology Index across key currencies, alongside an active expansion and repositioning of the portfolio. Increased large-cap exposure, new investments and a dense catalyst calendar support the outlook for the coming quarters.

BB Biotech: Share price resilience as portfolio is reshaped

A resilient Q1 2026 performance saw outperformance versus the Nasdaq Biotechnology Index across key currencies, alongside an active expansion and repositioning of the portfolio. Increased large-cap exposure, new investments and a dense catalyst calendar support the outlook for the coming quarters.
27.04.2026